US Stock MarketDetailed Quotes

GSK GlaxoSmithKline

Watchlist
  • 39.580
  • +0.230+0.58%
Trading Jul 22 09:40 ET
80.71BMarket Cap14.09P/E (TTM)

GlaxoSmithKline Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

GlaxoSmithKline Earnings Date

Currency: GBP

Period

Q2 FY2024 Estimates

Jul 31, 2024

Revenue(YoY)

7.50B

+4.55%
EPS(YoY)

0.67

-18.01%
Analyst Rating

Strong Buy

Jul 22, 2024

GlaxoSmithKline Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: GBP

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 8.455B--
Jul 31, 20242024/Q2-- / 7.505B--
May 1, 20242024/Q17.363B / 7.060B--
--2023/Q48.052B / 7.621B--
Nov 1, 20232023/Q38.147B / 7.727B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 8.455B--
Jul 31, 20242024/Q2-- / 7.505B--
May 1, 20242024/Q17.363B / 7.060B--
--2023/Q48.052B / 7.621B--
Nov 1, 20232023/Q38.147B / 7.727B--

Unlock Free Earnings Estimates

GlaxoSmithKline Earnings Reports

  • 6-K: Gsk Makes a Strong Start to 2024 with Improving Outlook for the Year

    May 1 12:34 ET

  • GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F

    Mar 5 13:13 ET

  • GlaxoSmithKline | 20-F: Registration statement / Annual report / Transition report

    Mar 5 12:18 ET

  • GlaxoSmithKline | 6-K: Gsk Delivers Strong 2023 Performance and Upgrades Growth Outlooks

    Jan 31 13:02 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jul 22, 2024

    Strong Buy

    • Buy

      75.00%

    • Hold

      25.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg
    Concept CAR-T Therapy
    CAR-T Therapy
    Intraday+0.70%